Tag Archives: icosapent ethyl

Introduction Atrial fibrillation (AF) is a common arrhythmia with significant associated morbidity, mortality, and healthcare costs.1 N-3 fatty acids may influence the risk of AF, but previous studies show conflicting evidence on whether N-3 fatty acids are pro- or anti-arrhythmogenic. Given the significant cardiovascular disease risk reduction associated with N-3 fatty acids, there has been interest in delineating their risk profile. In 2004, Mozaffarian et al. noted that increased dietary fish intake was associated with lower incidence of AF.2 Two separate studies suggested that higher levels of circulating long-chain N-3 fatty acid and doc

Background Sustained reduction of elevated cholesterol (particularly low-density lipoprotein cholesterol [LDL-C]) with currently available therapies is associated with reduced atherosclerotic cardiovascular (CV) events in both primary and secondary prevention.1 Nevertheless, some individuals continue to exhibit substantial residual CV risk, which is associated with higher concentrations of atherogenic cholesterol carried by circulating triglyceride (TG)-rich lipoproteins. The failure to reduce CV events through TG reduction in statin-treated patients with niacin, fibrates and a carboxylic acid formulation of omega-3 polyunsaturated fatty acid

Introduction Multiple epidemiologic studies have identified elevated levels of blood triglycerides (TGs) or the phenotypic state of hypertriglyceridaemia (HTG) as being associated with an elevated risk of cardiovascular (CV) disease.1 Among therapies demonstrating significant reduction in TGs – beyond fibrates, niacin and statins – are marine-derived omega-3 polyunsaturated fatty acids (n-3 PUFAs); they consist principally of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Notably, the first Gruppo Italiano per lo Studio della Streptochiansi nell’Infarto (GISSI) supported a potential role of n-3 PUFAs in reducing death, non-

Introduction Originally, icosapent ethyl (IPE) was developed as a treatment for hypertriglyceridaemia.2 However, in the Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial (REDUCE-IT),3 IPE significantly decreased the risk of ischaemic events (including cardiovascular [CV] death) by ~25% after a median follow-up of 4.9 years. The study included patients with fasting triglyceride (TG) levels of 1.7 to 5.6 mmol/L (150 to 499 mg/dL) and low-density lipoprotein cholesterol (LDL-C) levels of 1.1 to 2.6 mmol/L (41 to 100 mg/dL) who were on optimum statin treatment. Interestingly, this reduction in CV risk was independent of